Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos J Petropoulos

Showing results (1-10 of 149) with videos related to

Pageof 15
Sort By:
AIDS (London, England)|April 18, 2003
Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistanceNeil T Parkin, Colombe Chappey, Christos J Petropoulos
Current Opinion in Infectious Diseases|January 14, 2005
Assessing chemokine co-receptor usage in HIVEoin Coakley, Christos J Petropoulos, Jeannette M Whitcomb
Antimicrobial Agents and Chemotherapy|June 5, 2013
Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravirWei Huang, Arne Frantzell, Signe Fransen, et al.
Molecular Biology and Evolution|September 29, 2016
Epistasis and Pleiotropy Affect the Modularity of the Genotype-Phenotype Map of Cross-Resistance in HIV-1Robert Polster, Christos J Petropoulos, Sebastian Bonhoeffer, et al.
AIDS (London, England)|July 20, 2010
Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptorsJonathan Toma, Jeannette M Whitcomb, Christos J Petropoulos, et al.
Antimicrobial Agents and Chemotherapy|December 27, 2005
The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitorsNeil T Parkin, Soumi Gupta, Colombe Chappey, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2003
Rapid evolution of the neutralizing antibody response to HIV type 1 infectionDouglas D Richman, Terri Wrin, Susan J Little, et al.
Journal of Virology|May 4, 2012
Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivoSigne Fransen, Soumi Gupta, Arne Frantzell, et al.
Journal of Virology|October 29, 2003
Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasmaThomas B Campbell, Kristina Schneider, Terri Wrin, et al.
Journal of Virology|December 28, 2002
Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replicationWei Huang, Andrea Gamarnik, Kay Limoli, et al.
Pageof 15

Showing results (1-10 of 149) with videos related to

Sort By:
Pageof 15
AIDS (London, England)|April 18, 2003
Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistanceNeil T Parkin, Colombe Chappey, Christos J Petropoulos
Current Opinion in Infectious Diseases|January 14, 2005
Assessing chemokine co-receptor usage in HIVEoin Coakley, Christos J Petropoulos, Jeannette M Whitcomb
Antimicrobial Agents and Chemotherapy|June 5, 2013
Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravirWei Huang, Arne Frantzell, Signe Fransen, et al.
Molecular Biology and Evolution|September 29, 2016
Epistasis and Pleiotropy Affect the Modularity of the Genotype-Phenotype Map of Cross-Resistance in HIV-1Robert Polster, Christos J Petropoulos, Sebastian Bonhoeffer, et al.
AIDS (London, England)|July 20, 2010
Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptorsJonathan Toma, Jeannette M Whitcomb, Christos J Petropoulos, et al.
Antimicrobial Agents and Chemotherapy|December 27, 2005
The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitorsNeil T Parkin, Soumi Gupta, Colombe Chappey, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2003
Rapid evolution of the neutralizing antibody response to HIV type 1 infectionDouglas D Richman, Terri Wrin, Susan J Little, et al.
Journal of Virology|May 4, 2012
Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivoSigne Fransen, Soumi Gupta, Arne Frantzell, et al.
Journal of Virology|October 29, 2003
Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasmaThomas B Campbell, Kristina Schneider, Terri Wrin, et al.
Journal of Virology|December 28, 2002
Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replicationWei Huang, Andrea Gamarnik, Kay Limoli, et al.
Pageof 15